Ralliant (NYSE:RAL) Releases FY 2026 Earnings Guidance

Posted by Stanley Muller on May 14th, 2026

Ralliant (NYSE:RAL – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.530-2.690 for the period, compared to the consensus earnings per share estimate of 2.350. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion. Ralliant also updated its Q2 2026 guidance to 0.580-0.640 EPS.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RAL. Truist Financial reissued a “buy” rating and issued a $68.00 price target (up from $53.00) on shares of Ralliant in a research note on Wednesday. Zacks Research raised shares of Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. Barclays raised their price target on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday. Royal Bank Of Canada raised their price target on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Finally, Citigroup raised their price target on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ralliant presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.60.

Check Out Our Latest Research Report on RAL

Ralliant Price Performance

Shares of RAL stock opened at $61.41 on Thursday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 0.58. The firm’s 50-day moving average is $44.88 and its two-hundred day moving average is $47.32. Ralliant has a 12 month low of $37.27 and a 12 month high of $62.35. The company has a market capitalization of $6.87 billion and a PE ratio of -5.61.

Ralliant (NYSE:RAL – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company had revenue of $534.60 million for the quarter. The firm’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts predict that Ralliant will post 2.37 earnings per share for the current year.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s payout ratio is 10.20%.

Insider Buying and Selling

In other Ralliant news, SVP Karen M. Bick sold 5,485 shares of Ralliant stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total transaction of $246,825.00. Following the transaction, the senior vice president directly owned 46,756 shares of the company’s stock, valued at $2,104,020. The trade was a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

Positive Sentiment: Ralliant reported Q1 EPS of $0.57, beating estimates of $0.49, on revenue of $534.6 million, which rose 11% year over year. The earnings beat and solid sales growth are supporting the stock. Ralliant earnings report
Positive Sentiment: The company raised full-year 2026 guidance, with EPS now expected at $2.53-$2.69 versus the prior outlook and above Wall Street expectations, reinforcing confidence in the company’s growth trajectory. Ralliant guidance article
Positive Sentiment: Ralliant also guided Q2 EPS to $0.58-$0.64 and revenue to $540 million-$556 million, both above consensus, suggesting momentum is continuing into the second quarter. Ralliant results and guidance
Positive Sentiment: Truist reaffirmed its buy rating and raised its price target to $68 from $53, signaling stronger analyst confidence after the earnings release. Benzinga analyst update
Positive Sentiment: The company announced a $100 million accelerated share repurchase, which can boost EPS and is often viewed as a sign management believes the shares are undervalued. Ralliant share repurchase

Hedge Funds Weigh In On Ralliant

A number of institutional investors have recently bought and sold shares of RAL. Cetera Investment Advisers purchased a new position in Ralliant during the second quarter worth about $700,000. Russell Investments Group Ltd. acquired a new stake in shares of Ralliant during the second quarter valued at about $1,465,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Ralliant during the second quarter valued at about $39,000. First Trust Advisors LP acquired a new stake in shares of Ralliant during the second quarter valued at about $2,013,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Ralliant during the second quarter valued at about $326,000.

About Ralliant

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.